NeuroSense Locks in December 2026 PrimeC NDS Filing After Health Canada Alignment
NRSN sits 40% above its 52-week low of $0.393.
Summary
Following a successful Pre-NDS process, NeuroSense is targeting a December 2026 filing for PrimeC in ALS with Health Canada, having secured alignment on submission content and no regulatory concerns.
Key Events · Product Development and Regulatory · NRSN
-
NDS Filing Target Set for December 2026
With successful Pre-NDS alignment on submission content and structure now complete, NeuroSense will file a New Drug Submission for PrimeC in ALS with Health Canada in December 2026.
-
Health Canada Endorses Filing Timeline
Clearing a key regulatory hurdle, Health Canada raised no concerns with the proposed timeline and advised targeting early December.
-
Phase 2b Survival Data Strengthens Package
The NDS will include a statistically significant ~15-month median survival benefit (HR 0.35, p=0.0037) from the PARADIGM study — a compelling differentiator in a market with limited treatment options.
-
Canadian Market Opportunity Quantified
Over 3,000 Canadians live with ALS, with ~1,000 new diagnoses annually. Current standard-of-care oral edaravone costs ~C$120,000 per patient per year, underscoring the commercial potential.
Analysis · NRSN · Life Sciences
A concrete regulatory path for PrimeC in ALS is now in place, with Health Canada endorsing the submission plan and a December 2026 filing target. This de-risks the Canadian approval timeline and provides a clear near-term catalyst. The disclosed survival benefit from Phase 2b — a 15-month median improvement with a hazard ratio of 0.35 — strengthens the clinical package. Against a backdrop of recent insider buying and a dwindling ATM facility, this regulatory progress marks a critical step toward potential commercialization and non-dilutive funding.
How filings like this one have moved
In the 30 days to Oct 18, 2026, 37.6% of the 940 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.76%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NRSN was trading at $0.55 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $20.8M. The 52-week trading range was $0.39 to $1.98. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.